Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Study of Marstacimab Prophylaxis in Hemophilia A and B
NCT05145127Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Nov 2021
- Primary completion
- Jul 2030
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of marstacimab in hemophilia A, hemophilia B (HB), sponsored by Pfizer. Started Nov 2021; status: recruiting.
02
Drugs
marstacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT05145127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05145127.